Invites Biocore Co., Ltd.

A216400

KR7216400002

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
8,800 ^KRW	-3.30%		-2.87%	-5.38%

2023	CrystalGenomics Invites Co., LTD. agreed to acquire an 89.95% stake in PROCAGEN from Invites Biocore Co., Ltd. and others for KRW 13.1 billion	CI
2023	Invites Healthcare Co., Ltd. agreed to acquire Invites Genomics Co., Ltd. from Invites Biocore Co., Ltd. for KRW 10 billion	CI

Invites Healthcare Co., Ltd. agreed to acquire Invites Genomics Co., Ltd. from Invites Biocore Co., Ltd. for KRW 10 billion

May 16, 2023

Invites Healthcare Co., Ltd. agreed to acquire Invites Genomics Co., Ltd. from Invites Biocore Co., Ltd. (XKON:A216400) for KRW 10 billion on May 17, 2023.

Latest news about Invites Biocore Co., Ltd.

CrystalGenomics Invites Co., LTD. agreed to acquire an 89.95% stake in PROCAGEN from Invites Biocore Co., Ltd. and others for KRW 13.1 billion	Dec. 27	CI
Invites Healthcare Co., Ltd. agreed to acquire Invites Genomics Co., Ltd. from Invites Biocore Co., Ltd. for KRW 10 billion	23-05-16	CI
Invites Biocore Co., Ltd. completed the acquisition of 85% stake in PROCAGEN from Byun Seok-soo.	22-07-14	CI
Invites Biocore Co., Ltd. agreed to acquire 85% stake in PROCAGEN from Byun Seok-soo.	22-07-13	CI
Biocore Co., Ltd. announced that it has received KRW 41.999997 billion in funding	21-03-30	CI
Biocore Co., Ltd. announced that it expects to receive KRW 41.999997 billion in funding	21-02-16	CI
BioCore Inc. Signs Agreement with Osprey Medical, Inc	20-11-25	CI
Biocore Co., Ltd. announced that it has received KRW 7.99999527 billion in funding	20-07-07	CI
Invites Healthcare Co., Ltd. agreed to acquire a 20.03% stake in Biocore Co., Ltd. from Hongkong Dian Biotechnology Co., Limited for KRW 12 billion.	20-06-30	CI
Biocore Co., Ltd. announced that it expects to receive KRW 7.99999527 billion in funding	20-06-29	CI
Biocore Co., Ltd. announced that it expects to receive KRW 5.04114275 billion in funding	19-09-30	CI
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1, MAVI New Growth Good Corporation Investment Fund No. 2 acquired 2.67% stake in Biocore Co., Ltd. from Kwanghyun Lee and Seunghyun Lee for KRW 2.1 billion.	16-08-02	CI
Kiwoom Securities Co., Ltd. acquired approximately 1.8% stake in Biocore Co., Ltd. from SCL Healthcare Co., Ltd. and Kyungryul Lee for approximately KRW 1.6 billion.	16-08-01	CI
IBKC-SBI Bio Fund 1 of SBI Investment Korea Co., Ltd., MAGNA Investment Co., Ltd., MGI Secondary Fund 1 of MG Investment Co., Ltd. and SEMA-InterVest Bio Healthcare Fund of InterVest Co., Ltd. acquired additional 5.56% stake in Biocore Co., Ltd. from Lee, Kyungryul for KRW 4.9 billion.	16-08-01	CI
SBI Investment Korea Co., Ltd. through its SBI-Growth Ladder KONEX Vitalization Fund acquired 2.3% stake in Biocore Co., Ltd. from Kyungryul Lee for KRW 1.9 billion.	16-07-28	CI
Moon-Kyu Gong acquired 1.22% stake in Biocore Co., Ltd. from Jeong-Woo Lee for KRW 700 million.	15-10-27	CI
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1 and MAVI New Growth Good Corporation Investment Fund No. 2 acquired 8.88% stake in Biocore Co., Ltd. from Kwang-Hyun Lee and Seung-Hyun Lee for KRW 4 billion.	15-10-27	CI
Biocore Co., Ltd. completed the acquisition of Cytogenetic and Human Genome division of Seoul Clinical Laboratories.	15-10-21	CI
Biocore Co., Ltd. agreed to acquire Cytogenetic and Human Genome division of Seoul Clinical Laboratories for KRW 2.9 billion.	15-08-18	CI
Intelsius Announces Partnership with Biocore Co. Ltd. in South Korea	12-03-27	CI

Chart Invites Biocore Co., Ltd.

Duration

Period

More charts

Invites Biocore Co Ltd, formerly BioCore Co Ltd, is a Korea-based company mainly engaged in the provision of medical examination services. The Company operates its business through two segments. The New Drug Development Business segment is involved in the provision of bioequivalence testing, drug in vivo kinetics research, drug analysis in biological samples, toxicity kinetics testing, microanalysis in pharmaceuticals, comparative dissolution testing, and clinical trial consulting. The Biotechnology Business segment is engaged in the provision of customized genome analysis services and the manufacture and sale of diagnostic kits. The Companyâs products are sold under the brand of Bio-Core.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
INVITES BIOCORE CO., LTD.	-5.38%	49.03M
EXACT SCIENCES CORPORATION	-19.78%	10.91B
IOVANCE BIOTHERAPEUTICS, INC.	+44.90%	3.3B
GUARDANT HEALTH, INC.	-33.46%	2.19B
BGI GENOMICS CO., LTD.	-14.31%	2.16B
VERACYTE, INC.	-28.86%	1.5B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+25.34%	1.09B
SEEGENE, INC.	-3.28%	737M
CAREDX, INC	-35.33%	404M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-46.53%	386M

Bio Diagnostics & Testing

Invites Biocore Co., Ltd.

Equities

A216400

KR7216400002

Biotechnology & Medical Research

Invites Healthcare Co., Ltd. agreed to acquire Invites Genomics Co., Ltd. from Invites Biocore Co., Ltd. for KRW 10 billion

Latest news about Invites Biocore Co., Ltd.

Chart Invites Biocore Co., Ltd.

Company Profile

Sector Bio Diagnostics & Testing